Dr Bock, under the mentorship of Distinguished Professor Dietmar Hutmacher, from QUT Centre for Biomedical Technologies, has focused her research on bone metastases from breast and prostate cancers.

Clascoterone 5%, a topical anti-androgen drug indicated for male pattern hair loss, demonstrated significant hair regrowth ...

Real-world data show that a combination of a first-generation anti-androgen drug and androgen deprivation therapy is no better than ADT alone in improving outcomes among men with metastatic castration ...

Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein used to infect cells and stop the progression of severe COVID-19 disease, suggests a new preclinical study from ...

Concomitant anti-androgen therapy may ameliorate the worse outcomes associated with delayed salvage radiation therapy for recurrent prostate cancer after radical surgery. Concomitant use of ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.

Anti-androgen therapy is commonly used to treat patients with advanced prostate cancer at stages where the disease has spread to the bones. However, new research has found that anti-androgen treatment ...

Testosterone kinetics in the first cycle of intermittent androgen deprivation (IAD) for men with localized or biochemical relapse (BR) of prostate cancer (PC) No significant financial relationships to ...

Hair loss has frustrated millions of men worldwide for decades, with few truly novel treatments emerging beyond minoxidil and oral anti-androgens. But 2025 may mark a turning point. A company-backed ...

Androgens like testosterone are male hormones that help regulate sex characteristics in the body. Everyone has androgens, but those born with male sex traits typically have higher levels. Here’s what ...